English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers at the Case Western Reserve School of Medicine have found that semaglutide may lower the risk of Alzheimer’s disease in people with type 2 diabetes (T2D).
Tag: semaglutide
Popular diabetes and weight-loss drug associated with lower opioid overdose risk
Case Western Reserve University School of Medicine identifies a potential new approach to address the opioid overdose epidemic—which has devastated families and communities nationally. Semaglutide was found to lower opioid overdoses in people with opioid-use disorder (OUD) and type 2 diabetes (T2D).
Combining Two Diabetes Drugs Helps Promote Weight Loss and Blood Sugar Control
New research finds a combination of drugs improves weight loss, glucose control and insulin resistance better than either drug alone. Using two diabetes medications together, such as a semaglutide like Ozempic or Rybelsus, with a second, newer class of drug, may offer a noninvasive solution to help people with Type 2 diabetes lose weight and manage their condition without the need for bariatric surgery.
New study shows popular diabetes and weight-loss drugs associated with lower risk for tobacco-use disorder
A new study by researchers at the Case Western Reserve School of Medicine reveals popular diabetes and weight-loss drugs are linked to a lower risk for tobacco-use disorder (TUD) in smokers with type 2 diabetes, compared with seven other anti-diabetes medications.
Semaglutide may show promise for smoking cessation
New use of semaglutide was associated with a lower risk for medical care related to tobacco use disorder (TUD) in smokers with type 2 diabetes compared with 7 other anti-diabetes medications.
New Cedars-Sinai Study Investigates Shifting Trends in GLP-1RA Prescription
Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States.
Data shows surge in in new GLP-1RA prescriptions for obesity without type 2 diabetes
A nationwide study found a marked increase in new GLP-1RA prescriptions over the last decade, particularly since 2020. Semaglutide was the most prescribed GLP-1RA, by far, in 2023.
The Medical Minute: What to know about Ozempic and weight loss drugs
Weight-loss drugs are all over the news these days. A Penn State Health expert helps separate fact from fiction and determine what’s the safest alterative for the people who need them.
UNC Health Researchers Present Preliminary Data on Weight Loss Drugs on Alcohol Addiction
Christian Hendershot, PhD, associate professor of psychiatry and director of the Clinical and Translational Addiction Research Program at the UNC School of Medicine, presented early findings from the first completed randomized controlled trial of semaglutide for reducing alcohol consumption in heavy drinkers.
Semaglutide suitable for people with HIV and fatty liver disease
A study of persons with HIV (PWH) and metabolic dysfunction–associated steatotic liver disease, also known as ‘fatty liver disease,’ (MASLD) found that semaglutide was highly effective at reducing liver fat and cardiovascular disease risk in this population.
WEGOVY APPROVED FOR HEART RISK: U-Mich cardiology, obesity medicine experts available for interview
On March 8, the U.S. Food and Drug Administration approved a new indication for the use of semaglutide (brand Wegovy) to “reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or…
Obesity drugs and mental health: UTSW expert says GLP-1s may exacerbate problems for some patients
New weight-loss drugs have helped people with their diabetes, obesity, even high blood pressure. But how they affect our mental health is a much more complicated issue, says Dr. Carrie McAdams, a psychiatrist and eating disorders expert at UT Southwestern…
Physician Dispels Myths and Shares Insight Ahead of American Diabetes Month
More than 37 million Americans have been diagnosed with diabetes, with another 8.5 million believed to be living with the condition undiagnosed. In addition, 38 percent of the United States adult population is estimated to have prediabetes, a serious condition…
Phase II Trial Studies Effects of Semaglutide Medication in Patients with NASH
Nonalcoholic steatohepatitis (NASH)-related cirrhosis can lead to serious liver-related outcomes. In a phase 2 trial, lead author Rohit Loomba, MD, University of California San Diego School of Medicine, and collaborators, report semaglutide 2.4 mg once weekly in patients with NASH-related cirrhosis…
Three Kidney Transplants, Weight Gain and a Journey Back to Wellness
Rowena Roque, 46, was having a problem that many people can relate to: doing everything in her power to lose weight and get healthy but never succeeding.